Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

Encorafenib (Braftovi; Pierre Fabre Limited) plus binimetinib (Mektovi; Pierre Fabre Limited) is indicated for 'the treatment of adult patients with advanced non-small-cell lung cancer with a BRAF V600E mutation'.

The dosage schedule is available in the summary of product characteristics for encorafenib.

Encorafenib costs £1,400 for a 42‑pack of 75 mg capsules and binimetinib costs £2,240 per 84‑pack of 15 mg tablets (excluding VAT; BNF online accessed May 2025).

The company has commercial arrangements for encorafenib and binimetinib. These make encorafenib and binimetinib available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on the company's webpage on sustainable development.